Help us transform the future of biologic drug delivery

Led by a respected, experienced team and headquartered in Glasgow, UK, Nebu~Flow has built momentum through high-value pharma collaborations and prestigious awards. With five patent families secured, prototype devices validated and active engagement with patients, carers and healthcare providers, we’re making fast progress towards our goal of bringing our next-generation nebuliser to market. We’re looking to raise our next investment round, so please get in touch if you’d like to know more. 

Progress to date

11.2m funding secured

  • £4.7M seed round closed in 2024

  • £1.75M equity funding

  • £1.25M Innovate UK grant

  • £2M SE 2026

  • Other small grant awards

11.2m funding secured

  • £4.7M seed round closed in 2024

  • £1.75M equity funding

  • £1.25M Innovate UK grant

  • £2M SE 2026

  • Other small grant awards

11.2m funding secured

  • £4.7M seed round closed in 2024

  • £1.75M equity funding

  • £1.25M Innovate UK grant

  • £2M SE 2026

  • Other small grant awards

11.2m funding secured

  • £4.7M seed round closed in 2024

  • £1.75M equity funding

  • £1.25M Innovate UK grant

  • £2M SE 2026

  • Other small grant awards

5 patent families secured

  • 5 patent families protection through 2040+

  • Prototypes validated for biologics

  • Derisked scaleup and manufacturing

  • 3 LOIs and active pharma collaborations

5 patent families secured

  • 5 patent families protection through 2040+

  • Prototypes validated for biologics

  • Derisked scaleup and manufacturing

  • 3 LOIs and active pharma collaborations

5 patent families secured

  • 5 patent families protection through 2040+

  • Prototypes validated for biologics

  • Derisked scaleup and manufacturing

  • 3 LOIs and active pharma collaborations

5 patent families secured

  • 5 patent families protection through 2040+

  • Prototypes validated for biologics

  • Derisked scaleup and manufacturing

  • 3 LOIs and active pharma collaborations

The market

Primary target: Inflammation

8-10% CAGR

‘To and through the lung’:

  • Vaccines

  • Oligonucleotides

  • RNAs

  • T-Cell targets

  • Peptides

  • mAbs

  • No-type 2 (T2) mechanisms

  • ILD 6

Large growing markets

Respiratory $50B+, Biologics $500B+, Nebulisers $2B+
Visual diagram of Nebu~Flow airflow system and connected components

Market strategy

Target customers

  • Biopharma companies developing inhalable biologics

  • Clinical-stage innovators seeking better delivery platforms

  • Venture portfolios with high-potential biological assets

  • Respiratory service sector

Opportunities

  • Service fees from partnerships

  • Licensing of IPR

  • Milestones and royalties

  • Device sales

  • Inhalation data monetisation

Backed by brilliant life science investors:

Foresight logo
Foresight logo
Science Creates logo
Science Creates logo
Life Fund logo
Life Fund logo
Sis Ventures logo
Sis Ventures logo
WAE A Fortescue Company logo
WAE A Fortescue Company logo

Industry recognition

Nebu~Flow’s leadership team and advisory board are experts in pharma, technology and finance, with deep knowledge in respiratory drug delivery, acoustic technology and developing successful businesses. The company been featured at leading drug delivery and respiratory innovation forums, and has won a number of prestigious science and business awards, including CPHI Global Start-Up of the Year (2024)

CPHI Winner
CPHI Winner
Scottish Edge Higgs Winner
Scottish Edge Higgs Winner

Sign up for our latest news and updates

By signing up you agree to our privacy policy.

© 2026 Acu-Flow Limited (trading as Nebu-Flow®) Registered number: SC624449

Sign up for our latest news and updates

By signing up you agree to our privacy policy.

© 2026 Acu-Flow Limited (trading as Nebu-Flow®) Registered number: SC624449

Sign up for our latest news and updates

By signing up you agree to our privacy policy.

© 2026 Acu-Flow Limited (trading as Nebu-Flow®) Registered number: SC624449

Sign up for our latest news and updates

By signing up you agree to our privacy policy.

© 2026 Acu-Flow Limited (trading as Nebu-Flow®) Registered number: SC624449